Select Medical Holdings Corporation’s recent filing unveils that its Director Khanuja Parvinderjit S. acquired Company’s shares for reported $0.32 million on May 05 ’25. In the deal valued at $15.02 per share,21,000 shares were bought. As a result of this transaction, Khanuja Parvinderjit S. now holds 65,089 shares worth roughly $1.01 million.
Then, CHERNOW DAVID S sold 225,000 shares, generating $4,050,000 in total proceeds. Upon selling the shares at $18.00, the CEO now owns 714,516 shares.
Before that, CHERNOW DAVID S bought 225,000 shares. Select Medical Holdings Corporation shares valued at $4,050,000 were divested by the Officer at a price of $18.00 per share.
Mizuho initiated its Select Medical Holdings Corporation [SEM] rating to an Outperform in a research note published on April 16, 2025; the price target was $25. A number of analysts have revised their coverage, including The Benchmark Company’s analysts, who increased its forecast for the stock in late February from “a Hold” to “a Buy”. The Benchmark Company also remained covering SEM and has decreased its forecast on November 25, 2024 with a “Hold” recommendation from previously “Buy” rating.
Price Performance Review of SEM
On Friday, Select Medical Holdings Corporation [NYSE:SEM] saw its stock jump 0.32% to $15.49. Over the last five days, the stock has gained 2.31%. Select Medical Holdings Corporation shares have fallen nearly -17.82% since the year began. Nevertheless, the stocks have fallen -16.46% over the past one year.
Levels Of Support And Resistance For SEM Stock
How much short interest is there in Select Medical Holdings Corporation?
A steep rise in short interest was recorded in Select Medical Holdings Corporation stocks on 2025-05-15, dropping by 57694.0 shares to a total of 4.15 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 4.21 million shares. There was a decline of -1.39%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 13, 2021 when The Benchmark Company resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $44.
